Therapy Acceleration Program®

Strategic Venture Philanthropy Funding Initiative Since 2007

Please join The Leukemia & Lymphoma Society's Therapy Acceleration Program® (TAP) leadership for a one hour discussion panel to learn more about LLS TAP and to hear from past and current TAP portfolio partners on how LLS TAP creates value for each company.

Download the event flyer or for more information and to register click here.


What is TAP?

TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.

Since its establishment in 2007, TAP has invested more than $120 million in over 60 projects.

Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):

  • CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML)1
  • Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL)2
  • Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)3

Currently, there are over 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies. (click here for portfolio).

Download a presentation that describes more about TAP.


How can TAP benefit your company?

Listen to what the Chief Medical Officer of Forty Seven, Chris Takimoto, has to say about TAP and the value created for his company.

Recently Forty Seven was acquired by Gilead Sciences for $4.9 Billion.